Canada Markets closed

Lucid Diagnostics Inc. (LUCD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1500+0.0800 (+3.86%)
At close: 04:00PM EDT
2.0700 -0.08 (-3.72%)
After hours: 04:38PM EDT

Lucid Diagnostics Inc.

One Grand Central Place
Suite 4600 60 East 42nd Street
New York, NY 10165
United States
212 949 4319
https://www.luciddx.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Lishan Aklog M.D.Chairman & CEON/AN/A1966
Dr. Sanford D. Markowitz M.D., Ph.D.Cofounder & Strategic Advisor, Member of the Medical Advisor Board41.26kN/AN/A
Mr. Dennis M. McGrath CPACFO, Pres & Sec.N/AN/A1957
Dr. Joseph Willis M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardN/AN/AN/A
Dr. Amitabh Chak M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardN/AN/AN/A
Mr. Shaun O'Neill M.B.A.Exec. VP & COON/AN/A1982
Richard D. YazbeckChief Technology OfficerN/AN/AN/A
Dr. Suman M. Verma M.D., Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Adrian K. MillerVP of Investor RelationsN/AN/AN/A
Dr. Brian J. deGuzman M.D.Chief Compliance OfficerN/AN/A1965
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, a esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Corporate Governance

Lucid Diagnostics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.